529 related articles for article (PubMed ID: 19652987)
21. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
[TBL] [Abstract][Full Text] [Related]
22. [Diffuse pulmonary hemorrhage associated with antineutrophil cytoplasmic antibodies. Findings of high-resolution computerized tomography. A case report].
Galeotti R; Sala S; Rosina G; Mannella P
Radiol Med; 1997 Dec; 94(6):685-7. PubMed ID: 9524614
[No Abstract] [Full Text] [Related]
23. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
24. [Initial results of multicenter, randomized, controlled therapy studies for ANCA-associated vasculitis].
de Groot K
Z Rheumatol; 2003 Apr; 62(2):116-7. PubMed ID: 12820617
[No Abstract] [Full Text] [Related]
25. Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials.
Vanková Z; Ríhová Z; Jancová E; Rysavá R; Merta M; Tesar V
Prague Med Rep; 2006; 107(2):199-212. PubMed ID: 17066740
[TBL] [Abstract][Full Text] [Related]
26. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
Harper L
Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
[TBL] [Abstract][Full Text] [Related]
27. Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study.
Yuan J; Fang W; Zhang W; Ni Z; Qian J
Nephrology (Carlton); 2011 May; 16(4):440-5. PubMed ID: 21091923
[TBL] [Abstract][Full Text] [Related]
28. [Immunosuppressive therapy update 2010 for ANCA-associated glomerulonephritis and intractable nephrotic syndrome].
Yoshida M
Nihon Jinzo Gakkai Shi; 2010; 52(1):1-9. PubMed ID: 20166533
[No Abstract] [Full Text] [Related]
29. The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.
Menahem S; Hiremagalur B; Mudge D; Toussaint N; Walters G;
Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S24-36. PubMed ID: 18713121
[No Abstract] [Full Text] [Related]
30. [ANCA-positive vasculitis of the skin and kidneys associated with acne conglobata].
Manz B; Rytter M; Mittag M; Seidel W; Nenoff P
Hautarzt; 2002 Nov; 53(11):730-4. PubMed ID: 12402135
[TBL] [Abstract][Full Text] [Related]
31. Association of ANCA-positive vasculitis with thyroid disease.
Rothe HM; Siegmund J; Müller H; Wopperer J
Nephrol Dial Transplant; 2008 Jun; 23(6):2107; author reply 2107-8. PubMed ID: 18323519
[No Abstract] [Full Text] [Related]
32. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Metzler C; Miehle N; Manger K; Iking-Konert C; de Groot K; Hellmich B; Gross WL; Reinhold-Keller E;
Rheumatology (Oxford); 2007 Jul; 46(7):1087-91. PubMed ID: 17519271
[TBL] [Abstract][Full Text] [Related]
33. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
35. [Hypertrophic pachymeningitis, glomerulonephritis and P-ANCA associated small vessel vasculitis].
Mazzocchi O; Risso JA; Viozzi F; Apa NP; Peralba MC; Nadal MA; De Rosa GE
Medicina (B Aires); 2007; 67(2):151-5. PubMed ID: 17593600
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
[TBL] [Abstract][Full Text] [Related]
37. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Sanders JS; Slot MC; Stegeman CA
N Engl J Med; 2003 Nov; 349(21):2072-3; author reply 2072-3. PubMed ID: 14627795
[No Abstract] [Full Text] [Related]
38. Evidence-based management of ANCA vasculitis.
Carruthers D; Sherlock J
Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):367-78. PubMed ID: 19508944
[TBL] [Abstract][Full Text] [Related]
39. Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment.
Zaenker M; Arbach O; Helmchen U; Glorius P; Ludewig S; Braasch E
Int J Tissue React; 2004; 26(3-4):85-92. PubMed ID: 15648440
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis und therapy of ANCA-associated vasculitis].
Aries PM; Hellmich B; Gross WL
Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
